Drug Profile
Research programme: visceral leishmaniasis therapeutics - Advinus Therapeutics/DNDi/Global Alliance for TB Drug Development
Alternative Names: DNDI-8219; VL-2098Latest Information Update: 02 Aug 2019
Price :
$50
*
At a glance
- Originator Global Alliance for TB Drug Development
- Developer Advinus Therapeutics; Drugs for Neglected Diseases Initiative Foundation
- Class Nitroimidazoles
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Visceral leishmaniasis
Most Recent Events
- 02 Aug 2019 Discontinued - Preclinical for Visceral leishmaniasis in India (PO)
- 02 Aug 2019 Discontinued - Preclinical for Visceral leishmaniasis in Switzerland (PO)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Visceral-leishmaniasis in India (PO)